1.
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Glob...
by Abd-Allah, Foad
The Lancet (British edition), 2017, Vol.390 (10100), p.1211-1259
2.
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016:...
by Abate, Kalkidan Hassen
The Lancet (British edition), 2017, Vol.390 (10100), p.1260-1344
3.
Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
by Seitz, Anna Katharina
European journal of nuclear medicine and molecular imaging, 2017, Vol.45 (4), p.602-612
4.
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
by Fanti, Stefano
European journal of nuclear medicine and molecular imaging
5.
Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer
by Dost, Rutger J
European journal of nuclear medicine and molecular imaging, 2013, Vol.40 (Suppl 1), p.S41-S47
6.
MicroRNAs in prostate cancer: Functional role as biomarkers
by Kanwal, Rajnee
Cancer letters, 2017, Vol.407, p.9-20
7.
Use of two gene panels for prostate cancer diagnosis and patient risk stratification
by Xiao, Kefeng
Tumor biology, 2016, Vol.37 (8), p.10115-10122
9.
Metastatic Prostate Cancer: Treatment Options
by Achard, Vérane
Oncology, 2022, Vol.100 (1), p.48-59
10.
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
by Du, Yong
European journal of nuclear medicine and molecular imaging, 2017, Vol.44 (10), p.1671-1678
11.
Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men
by Dankner, Rachel
Diabetologia, 2016, Vol.59 (8), p.1683-1691
12.
Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study
by Herden, Jan
Urologia internationalis, 2021, Vol.105 (5-6), p.428-435
13.
Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Tu...
by Çelik, Serdar
Urologia internationalis, 2022, Vol.106 (1), p.35-43
14.
Sequencing strategies in the new treatment landscape of prostate cancer
by Caffo, Orazio
Future oncology (London, England), 2019, Vol.15 (25), p.2967-2982
15.
To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
by Caffo, Orazio
Expert review of anticancer therapy, 2021, Vol.21 (4), p.389-400
16.
PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
by Giesel, Frederik L
European journal of nuclear medicine and molecular imaging, 2015, Vol.42 (12), p.1794-1800
17.
HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer
by Chang, Yi-Ting
Cancer letters, 2018, Vol.433, p.43-52
18.
Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease
by Porcaro, Antonio Benito
Urologia internationalis, 2019, Vol.103 (4), p.391-399
19.
First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
by Zang, Jie
European journal of nuclear medicine and molecular imaging, 2018, Vol.46 (1), p.148-158
20.
Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3
by Hu, Fei
Cancer letters, 2018, Vol.416, p.24-30
